Login
Companies $CUE
$13.80 -$0.30 (2.13%) After hours
Cue Biopharma, Inc. logo

Cue Biopharma, Inc.

cuebiopharma.com

What Do They Do?

Develops injectable biologic therapies that target disease-specific T cells for autoimmune and inflammatory diseases, and licensed cancer therapies for development by partners.

How Do They Make Money?

Partners pay upfront fees for licenses, research and development support, and payments when development or sales milestones are reached; royalties may follow when licensed products are sold. License fees may be paid when the partner receives the rights, while research services can bring payments over the course of the work.

FY2025 revenue

Who Are Their Customers?

Biopharmaceutical partners license drug candidates and may fund research and development activities. IMSCP received a license to develop CUE-101 and CUE-102 for oncology; Boehringer Ingelheim is developing CUE-501.

Do Revenues Turn Into Profits?

No. It lost $26.6M in FY2025.

Operating income, FY2025
−97% of revenue
▲ +36% (Loss) vs FY2024 (−$41.5M, −447%)
Net income, FY2025
−97% of revenue
▲ +35% (Loss) vs FY2024 (−$40.7M, −438%)
Free cash flow, FY2025
−80% of revenue
▲ +40% (Loss) vs FY2024 (−$36.4M, −392%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
▲ +167%
vs $3M in Q2 FY2025
Net income
▼ −1705% (Loss)
vs −$8.5M in Q2 FY2025
  • Sep 20, 2026 CUE-221 Phase 2 CSU trial met its primary endpoint The study also met its key secondary endpoint at the highest dose, and Cue plans further development in chronic hives and food allergy.
  • Apr 27, 2026 Cue licensed Ascendant-221 for development and commercialization The antibody is in Phase 2 development for allergic diseases; Cue plans a food allergy trial after reviewing results from a China study.
  • Apr 1, 2026 Boehringer Ingelheim selected its first compound for lead optimization The selection triggered a $7.5 million payment to Cue under the collaboration agreement.

Growing. Revenue grew 84% in 4 years, from $14.9M in FY2021 to $27.5M in FY2025, about 16% a year.

Added an allergy drug candidate The older report focused on developing its own T-cell-targeting biologics, especially cancer programs. The latest report includes an anti-IgE antibody licensed from Ascendant for allergic diseases, alongside its autoimmune programs.

Shifted emphasis toward autoimmune programs The older report prioritized cancer drug development and sought partners for programs outside oncology. The latest report emphasizes autoimmune drug development and describes collaborations for additional programs.

Who Do They Compete With?

Competes with Amgen, Bristol-Myers Squibb, Merck &, Nektar Therapeutics, Sanofi, TRex Bio, RegCell, Coya Therapeutics, Quell Therapeutics, EVOQ Therapeutics, and Sonoma Biotherapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support